PEG IFN alfa-2a

DRUG2 trials

Sponsors

Hepatera Ltd.

Conditions

Chronic Hepatitis D InfectionChronic Viral Hepatitis B With Delta-agent

Phase 1

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

CompletedNCT02637999

Hepatera Ltd.Chronic Hepatitis D Infection

Start: 2014-02-13End: 2016-01-21Updated: 2018-04-13

Phase 2

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

CompletedNCT02888106

Hepatera Ltd.Chronic Viral Hepatitis B With Delta-agent

Start: 2016-04-30End: 2020-10-30Updated: 2021-04-30

Related Papers

Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐<scp>IFNα</scp>‐2a as Treatment for Chronic Hepatitis Delta

Liver International2025-01-248 citations

Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48

Liver International2024-12-0810 citations

Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies

Journal of Hepatology2024-02-0833 citations